Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.
Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A.
Stenehjem DD, et al. Among authors: agarwal am, agarwal n.
Cancer Immunol Immunother. 2016 Aug;65(8):941-9. doi: 10.1007/s00262-016-1854-1. Epub 2016 Jun 8.
Cancer Immunol Immunother. 2016.
PMID: 27277816
Free PMC article.